AllDocs -> cancers

EBMT European Group for Blood and Marrow Transplantation MED-B FORM LYMPHOMA For registration of ALLOGENEIC or AUTOLOGOUS Stem Cell Transplantation The specific questionnaire for each disease has been established by the responsible working party. Any request for modification and improvement should be first discussed at the level of the working party which will then transmit approved modifications to the EBMT registry sub-committee Copyright © by EBMT, 2003 All rights reserved Page 2 EBMT - MED B 2003 - LYMPHOMA - p. 1 INSTRUCTIONS FOR USE.2 G ENERAL I NFORMATION . 4 L YMPHOMA .. 5 F OLLOW UP : L YMPHOMA 9 APPENDIX A.14 NATIONAL REGISTRIES . 14 ...

33 Simultaneous occurrence of follicular lymphoma and mixed-cellularity Hodgkin’s lymphoma : lymph node and extranodal involvement Ocorrência simultânea de linfoma folicular e linfoma de Hodgkin celularidade mista: envolvimento nodal e extranodal Maria do Patrocínio F. Grangeiro 1 ; Sílvia Maria M. Magalhães 2 ; Francisco Valdeci A. Ferreira 1 ; Francisco Dário Rocha Filho 1 J Bras Patol Med Lab • v. 40 • n. 1 • p. 33-6 • fevereiro 2004 1. Professor of the Department of Pathology and Legal Medicine of Universidade Federal do Ceará (UFC)/Hemoce. 2. Professor of the Department of Clinical Medicine of UFC/Hemoce. abstract An unusual and well-characterised case of composite lymphoma in the spleen and lymph node is presented. The simultaneous occurrence of mixed-cellularity Hodgkin’s ...

Secondary Lymphoma of the Heart Presenting as Recurrent Syncope Rohit Manojkumar, Anurag Sharma, Anil Grover Department of Cardiology, Post Graduate Institute of Medical Education and Research, Chandigarh T he most common secondary tumors in pediatric patients are non-Hodgkin’s lymphoma , leukemia and neuroblastoma. 1 Cardiac involvement from non-Hodgkin’s lymphoma can present with pericardial ef fusion, arrhythmia and congestive heart failure. 2 Ventricular tachycardia (VT) as a presentation is rare. 3,4 We describe a case of metastatic non-Hodgkin’s lymphoma presenting with syncope due to recurrent VT. Case Report GS, a 12-year-old boy was admitted to the medical emergency department with recurrent syncope. He had four episodes of syncope in the past month. During the present admission, his pulse was ...

MDACC Diffuse Large B-Cell Lymphoma a (Page 1 of 5) (V1; 8/8/03) No No Note: If available, clinical trials should be considered as preferred treatment options for eligible patients. Yes Yes No Yes Low Risk High Risk PATHOLOGIC DIAGNOSIS INITIAL EVALUATION Hematopathology review of all slides with at least one paraffin block representative of the tumor. Rebiopsy if consult material is nondiagnostic. Adequate immunophenotyping to establish diagnosis b > Paraffin panel: CD45 (LCA),CD20 (26/Pan B), CD3;(optional - cytokeratin) or > Cell surface marker analysis by flow cytometry: kappa/lambda, CD45, CD3, CD5, CD19, CD10, TdT, CD14, CD13, CD33, CD20 Additional immunohistochemical studies to establish lymphoma subtype ...

(Page 1 of 1) CLINICAL STAGE LOCAL TREATMENT (V1; 9/26/03) No No Note: If available, clinical trials should be considered as preferred treatment options for eligible patients. Yes Yes No Yes Low Risk High Risk Non-Gastric MALT a Lymphoma Stage IE - II Clinical Trial or Locoregional Radiotherapy with or without Rituxan Surgery for certain sites (lung, breast [with or without Radiotherapy], skinc, thyroid, colon/small bowel) Stage III - IV low grade Stage IE - IV, MALTa lymphomas coexistent with large cell lymphoma b Treat per Diffuse Large B-Cell Lymphoma Guidelines (Page 1) a MALT = mucosal - associated lymphoid tissue. b DLBCL coexistent with MALT cell lymphoma is managed as ...

MDAC C Mantle Cell Lymphoma a (Page 1 of 2) INIT IA L E V A L UA T ION (V1; 6/2/03) No No Note: If available, clinical trials should be considered as preferred treatment options for eligible patients. Y es Y es No Y es Low Risk High Risk Hematopathology review of all slides with at least one paraffin block representative of the tumor. Rebiopsy if consult material is nondiagnostic. Adequate immunophenotyping to establish diagnosis b Paraffin Panel: CD20 (L26/Pan B). CD3, CD5, CD10, cyclin D1 (optional: CD43, kappa/lamdba) or Cell surface marker analysis by flow cytometry: kappa/lambda, CD19, CD20, CD5, CD23,CD10, CD25, FMC7, CD3, CD5/CD19 Coexpression Cytogenetics FISH for t(11;14) Frozen Section Panel: kappa/lambda, CD5, CD23, ...

haematologica 2004; 89(6):June 2004 Letters to the Editor 753 Intraventricular treatment of relapsed central nervous system lymphoma with the anti-CD20 antibody rituximab Most patients with primary central nervous system (CNS) lymphoma or systemic non-Hodgkin’s lymphoma (NHL) involving the CNS relapse after an initial response to treatment, often presenting with leptomeningeal dis- ease. 1 Since the majority of these lymphomas are B-cell neoplasms expressing the CD20 surface antigen treat- ment with the chimeric monoclonal antibody (Mab) rit- uximab might be a new therapeutic option. 2-4 Here, we report on 6 patients with relapsed CNS B-cell lymphoma who were treated with intraventricular or intrathecal applications of rituximab. One of these cases has already been reported. 5 haematologica ...

As a member of the Team in Training program, I have set a personal goal to raise a minimum of $3,000 for the Leukemia and Lymphoma Society. No matter how long it takes me to finish cycling 100 miles, leukemia and lymphoma patients throughout the world will be winners. So will you and I! I ride in honor of Andy Yost a current MDS patient, and my dad who passed away this past Christmas, also with MDS, a form of pre-leukemia. Check on my progress often at <http://www.cs.jhu.edu/~houlahan/bike>. -- Joanne Houlahan Ab a Donati P : out the Leukemia and Lymphoma Society: The Leukemia and Lymphom Society is a not-for-profit, voluntary health organization whose mission is to cure leukemia and its related cancers— lymphoma , multiple myeloma, and Hodgkin’s disease—and improve the quality of life of patients and their families. They are ...

37 LYMPHOMA OF THE BLADDER Case Report PRIMARY LYMPHOMA OF THE BLADDER KATIA R. M. LEITE, HOMERO BRUSCHINI, LUIZ H. CAMARA-LOPES Laboratory of Surgical and Molecular Pathology, Syrian Lebanese Hospital, São Paulo, SP, Brazil ABSTRACT Primary lymphomas of bladder are rare, have a good prognosis and present good response to chemotherapy. We report a case of primary lymphoma affecting the bladder of an 89-year old female patient who, despite full response to chemotherapy, presented recurrence and death 1 year after con- cluding the treatment. The authors emphasize the differential diagnosis due to the great differences concerning prognosis and therapeutic approach. Key words : bladder; neoplasms; lymphoma ; treatment Int Braz J Urol. 2004; 30: 37-9 Figure 1 – Magnetic resonance imaging, T1-weighted sequence showing thickening of vesical wall affecting ...

500 MJA Vol 177 4 November 2002 NOTABLE CASES The Medical Journal of Australia ISSN: 0025-729X 4 November 2002 177 9 500-501 ©The Medical Journal of Australia 2002 www.mja.com.au Notable Cases A 63-year-old man with rheumatoid arthritis presented with pain and swelling of his right buttock. Imaging and tissue biopsy revealed a diffuse large B-cell, non-Hodgkin’s lymphoma . The disease- modifying drugs he was taking, cyclosporin and methotrexate, were stopped, and the lymphoma resolved spontaneously without the use of chemotherapy. (MJA 2002; 177: 500-507) R HEUMATOID ARTHRITIS is a common disorder. Its various articular and extra-articular manifestations are well described, but less well known is the association between rheumatoid arthritis and malignancy. There is an intrinsic risk of lymphoma , particularly non-Hodgkin’s ...

Meeting Highlights INTRODUCTION Keynote Speaker: Dale G. Schaar, MD, PhD, Heme Malig- nancies, The Cancer Institute of New Jersey, New Brunswick, New Jersey Non-Hodgkin’s lymphoma (NHL) is a cancer of the lym- phatic system. Approximately 54,000 new cases of NHL are recorded each year. 1 The disease affects 19 in 100,000 persons, equivalent to a rate of 4% of all cancers. From the 1970s to the 1980s, the incidence of NHL accelerated by 3% to 4% each year. In the 1990s, the rate declined and is now slowing down. The etiology is unclear, but the disease predominates in males. Possible etiologic factors include: • infectious organisms, such as human T-cell leukemia/ lymphoma virus (HTLV-1), Epstein-Barr virus, Heli- cobacter pylori , hepatitis C virus • genetic and environmental factors and family aggregation of hematolymphoproliferative neoplasms, or ...

lymphoma LYMPHOMA RESEARCH FOUNDATION CLINICAL INVESTIGATOR CAREER DEVELOPMENT GRANT APPLICATION FORM (2005-08) COVER SHEET For LRF use only Proposal Number Receipt Date & Time DEADLINE FOR SUBMISSION: Must be received by LRF by 5:00PM EST on September 7, 2004: Please carefully read the ?Guidelines & General Information For Application? before completing this Application . 1. Project Title (Do not exceed 90 typewritten spaces) 2. Name of Applicant Degree(s) Department M.D. Ph.D. Other (specify) Institution Mailing Address City State Zip Code Country ...

CHAPTER 16 – HIV-ASSOCIATED MALIGNANCIES Section 2 – AIDS-Related Lymphoma (ARL) HIV/AIDS PRIMARY CARE GUIDE, FLORIDA AIDS EDUCATION AND TRAINING CENTER, UNIVERSITY OF FLORIDA, 2002 193 Section 2 – AIDS-Related Lymphoma (ARL) Manuel Guerra, MD Senior Attending Physician, Division of Hematology/Oncology, Department of Medicine, Mercy Hospital, Miami EPIDEMIOLOGY • In 1984, Non-Hodgkin’s Lymphoma (NHL) was described as one of the diseases with increased incidence/risk in the AIDS population • The incidence of NHL has increased in an almost parallel course with the AIDS epidemic and accounts for 2-3% of newly diagnosed AIDS cases • Lymphoma is a late manifestation of HIV disease - Serves as an initial AIDS-defining condition in approximately 3% of patients - Pre-HAART era: 12-16% of HIV-infected individuals thought to eventually die ...

For more information please contact us! ++49 (0) 89 / 8 95 55 9-30 www.genpharmtox.com ++49 (0) 89 / 8 95 55 9-18 Niels.Krebsfaenger@genpharmtox.de Mouse Lymphoma Assay 1. Purpose Mammalian cell culture systems can be used to detect mutations induced by chemical substances. One of the most commonly used mammalian cell mutagenesis system; the L5178Y TK+/- mouse lymphoma -TK assay detects the mutations at the thymidine kinase locus caused by base pair changes, frameshift and small deletions. Mutant cells, deficient in TK due to the forward mutation in the TK locus (from TK + to TK - ), are resistant to the cytotoxic effect of pyrimidine analogues such as trifluorothymidine (TFT). The mutagenicity of the test agents is indicated by the increase in the number of mutants after treatment. 2. ...

Cisco Systems, Inc. All contents are Copyright © 1992–2004 Cisco Systems, Inc. All rights reserved. Important Notices and Privacy Statement. Page 1 of 3 EXECUTIVE SUMMARY CUSTOMER NAME The Leukemia & Lymphoma Society INDUSTRY Healthcare BUSINESS CHALLENGE Raise additional funds Enhance patient and family support services Improve business communications and maintain monthly network operating costs NETWORK SOLUTION High-performance Cisco switches and routers Cisco VPN concentrators BUSINESS VALUE Enhanced communication facilitates patient and family support services and fund-raising event coordination Network infrastructure supports new technologies for enhancing business operations and reducing operating expenses ABSTRACT A Cisco foundation ...

lymphoma Anti-Cyclin D1 Gene Therapy for Mantle Cell Lymphoma Joya Mukerji MOL 523 April 30, 2004 Overview 1. What is mantle cell lymphoma (MCL)? (Epidemiology and lymphomagenesis) 2. How is MCL currently treated? 3. How could anti-cyclin D1 gene therapy be accomplished? How would it potentially benefit MCL patients? What is mantle cell lymphoma ? (I) Non-Hodgkin’s lymphomas rank ~6th among the causes of cancer-related deaths in the US (23,400 deaths in 2003). MCL is an aggressive malignancy of B-cells that comprises 5-10% of all non-Hodgkin’s lymphomas. MCL is typically diagnosed in individuals age 60 or over, with disseminated disease Median survival: 36 months No permanent remission Bertoni et al., 2004. British Journal of Haematology. ...

Bag Lunch for Lymphoma Registration Form As a Volunteer Coordinator, you have agreed to lead your groups-efforts of raising money for Lymphoma Research Foundation (LRF) and increasing awareness of lymphoma . LRF staff will be available throughout the campaign for any questions. Please choose the dates that best work for you. We are asking that you fill out the below information and either fax or send it to LRF, so we can count you in for the campaign. To reduce campaign costs, we are asking you to photocopy attached information about Lymphoma Research Foundation and educational materials about lymphoma to distribute to your participants. Additionally, you will be provided with blank thank you receipts to be filled out and given to donors who made contributions under $50. LRF will send thank you letters for donations over $50. Thank you again for your dedication. Fax: (212) ...

Johnhendrickfinal US Oncology PET Case Study – Lymphoma Courtesy of Dr. Galen Custer, Medical Oncologist – Kansas City Cancer Center Clinical Case Overview – Patient History: Patient had intermediate grade lymphoma in 1999. Persistent SPN early 2001 with no other evidence of disease. Why PET was ordered : This is the patient’s 1 st PET scan. It was ordered to evaluate SPN to recurrent lymphoma vs. new malignancy vs. benign change. PET Findings: SPN with increased uptake. Otherwise negative. Patient Treatment Management Change: Positive SPN, with no evidence of lymphoma elsewhere, justified surgery . Surgery proved that the nodule was in fact early stage low-grade lymphoma . This was different from the original histology which could be completely resected. Patient received their 3rd PET scan 8 months later: Following CT scan ...

From the GRCA Health and Genetics Committee GOLDENS WITH LYMPHOMA AND OSTEOSARCOMA ARE NEEDED TO STUDY THE GENETIC BASIS OF LYMPHOMA AND OSTEOSARCOMA Most Golden Retriever fanciers know Goldens that have died of lymphoma (cancer of the lymph nodes, lymphosarcoma) and osteosarcoma (bone cancer). Since our Goldens are predisposed to these cancers, many of us have lost some of our own beloved Goldens to these diseases. The Canine Health Foundation has funded a study that may help determine the genetic basis of these cancers. We have hopes that this study and subsequent studies may some day lead to genetic tests to identify Goldens predisposed to developing lymphoma and bone cancer and may identify those lymphomas and bone cancers most likely to respond to treatment. If your Golden Retriever is newly diagnosed with lymphoma or osteosarcoma (has not yet started chemotherapy, including steroids), ...

March 2004 Total registrations 46,624 New registrations 6915 (since EBMT 2002) Total number of centres 522 New centres 12 EBMT Lymphoma Registry Page 2 March 2004 Lymphoma transplants: by year of transplant 0 1000 2000 3000 4000 5000 6000 7000 8000 1978 1979 1980 1981 1982 1983 1984 1985 1986 1987 1988 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 20012002+ Year of transplant No. of transplants Page 3 March 2004 Lymphoma transplants: Classical vs reduced intensity conditioning 0 100 200 300 400 500 600 700 800 900 1000 <1995 1995 1996 1997 1998 1999 2000 ...

lymphoma Lymphoma Dr. David Lee Overview Concepts, classification, lymphomagenesis Epidemiology Clinical presentation Diagnosis Staging Three important types of lymphoma Conceptualizing lymphoma neoplasms of lymphoid origin, typically causing lymphadenopathy leukemia vs lymphoma lymphomas as clonal expansions of cells at certain developmental stages B-cell development stem cell lymphoid precursor progenitor-B pre-B immature B-cell mature naive B-cell germinal center B-cell Bone marrow Lymphoid tissue memory B-cell plasma cell DLBCL, FL, BL, HL LBL, ALL CLL MCL MM MZL CLL The challenge ...

INTRODUCTION Extranodal lymphoma of mucosa-associated lymphoid tis- sue (MALT) was first described by Isaacson and Wright in 1983 (1) and was recently reclassified as “extranodal marginal zone B-cell lymphoma (MZBL) of MALT-type ” according to the REAL (2) and WHO classifications (3). Primary MZBLs of MALT-type have been described in a variety of sites, includ- ing gastrointestinal tract (1), thyroid gland (4) , lung (5), sali- vary gland (6), and ocular adnexa (7) associated with clinical setting of autoimmune diseases or chronic inflammation, usu- ally Sjogren ’ s syndrome, Hashimoto ’ s thyroiditis, and Heli- cobacter pylori infection. Thymic MZBL of MALT-type is an extremely rare disease with only 22 cases having been report- ed in the literature to date and the largest series has included 15 cases (8-19). In this paper, I report a case of low-grade ...

Mayo Clin Proc, February 2004, Vol 79 Lymphoma Treatment in Severe Liver Dysfunction 169 Mayo Clin Proc . 2004;79:169-175 169 © 2004 Mayo Foundation for Medical Education and Research Original Articl Original Article Therapeutic Options in Patients With Lymphoma and Severe Liver Dysfunction I RENE M. G HOBRIAL , MD; R OBERT C. W OLF , P HARM D; D ENISE L. P EREIRA , MD; R AFAEL F ONSECA , MD; W ILLIAM L. W HITE , MD; J OSEPH P. C OLGAN , MD; T HOMAS M. H ABERMANN , MD; D AVID J. I NWARDS , MD; S VETOMIR ...

Mayo Clin Proc, January 2003, Vol 78 Running Head 187 Mayo Clin Proc . 2004;79:187 187 © 2004 Mayo Foundation for Medical Education and Research Medical Images P eau d’orange (French for orange peel) is characterized by edema and pitting and results from blockage of lymphatic drainage with or without associated stromal infiltration. The most common cause of breast peau d’orange is inflammatory breast cancer. However, the characteristic skin veneer is not always a sign of breast cancer and has also been described in cutaneous infection, sarcoidosis, and scleredema. A 62-year-old woman presented with refractory large cell lymphoma . Needle biopsy of her right breast revealed diffuse large B-cell lymphoma . The breast mass was initially resistant to combination chemotherapy but subsequently responded to radiation therapy to the involved field. Breast lymphomas, in the context of both ...

Pediatric Lymphoma B947 Biology Non-Hodgkin Hodgkin Lymphoblastic Anaplastic Large Cell Small Non- Cleaved Cell B-Large Cell Relapse Low Risk Intermediate Risk High Risk Relapse Standard of Care COG A 5971 Phase II: localized and disseminated K E Y Pending Suspended Open Revised 12/03/03 Team Leader Signature and Date COG AHOD0031 Phase III: Response-based Chemo & RT randomized COG AHOD0321 Phase II: Refractory Recurrent HD Gemcitabine & Vinorelbine COG AHOD0121 BMT for recurrent HD COG ANHL0131 Phase III: Study of TX of Advanced- Stage Anaplastic Large Cell Lymphoma ALCL with Standard APO Adriamycin, Prednisone, ...

G U I D E L I N E S Joint British Association of Dermatologists and U.K. Cutaneous Lymphoma Group guidelines for the management of primary cutaneous T-cell lymphomas S . J . W H I T T A K E R , J . R . M A R S D E N , * M . S P I T T L E A N D R . R U S S E L L J O N E S St John’s Institute of Dermatology, St Thomas’ Hospital, Lambeth Palace Road, London SE1 7EH, U.K. *Department of Dermatology, Selly Oak Hospital, Birmingham B29 6JD, U.K. Department of Dermatology, Ealing Hospital, Uxbridge Road, Southall UB1 3HW, U.K. Department of Oncology, Middlesex Hospital, Mortimer St, WIN 8AA, U.K. Accepted for publication 9 July 2003 These guidelines were commissioned by the British Association of Dermatologists guidelines and therapeutics subcommittee. Members of the committee are N.H.Cox (Chairman), A.S.Highet, D.Mehta, R.H.Meyrick Thomas, A.D.Ormerod, J.K.Schofield, C.H.Smith and J.C.Sterling. Members ...

Fact Sheet Radioimmunotherapy is a newly approved cancer treatment that combines two types of therapies– radiation therapy and immune therapy using monoclonal antibodies . Monoclonal antibodies are immune proteins made in the laboratory to target and attach to a special part (an antigen ) of the surface of a cell. Radiation–emitting molecules, referred to as radioisotopes , can be attached to the monoclonal antibodies. Those monoclonal antibodies targeted to cancer cells can carry the radiation–emitting molecule to the cancer cells, resulting in more localized, target–specific irradiation. Once attached to the surface of the cancer cell, the radioisotope may kill the cancer cells. Some normal cells that share the same antigen might also be killed. Radioimmunotherapy is being studied in several cancers, but has shown the most promise in the treatment of blood cell cancers, such as leukemia and ...

252 Korean J Radiol 4(4), December 2003 Primary Calcified T-Cell Lymphoma of the Urinary Bladder: A Case Report Primary malignant lymphoma of the urinary bladder is extremely rare, and to our knowledge, no case described in the radiologic literature has been accompa- nied by calcification. We report a case in which the condition was associated with calcification, and describe the pelvic CT and MR imaging findings. rimary lymphoma of the urinary bladder accounts for less than 1% of the neoplasms occurring in this organ. A few cases have been reported in the radiology literatures (1 3), but in no instance has been described associ- ated calcification. We report the CT and MR imaging findings in a patient with urinary bladder lymphoma involving internal calcification. CASE REPORT A 30-year-old woman presented with a two-month history of gross hematuria and ...

Trans Am Ophthalmol Soc / Vol 101 / 2003 275 MOLECULAR PATHOLOGY OF PRIMARY INTRAOCULAR LYMPHOMA BY Chi-Chao Chan MD ABSTRACT Purpose: To evaluate immunoglobulin heavy chain (IgH) gene rearrangements, cytokines and chemokines, and infec- tious agents in primary intraocular B-cell lymphoma (PIOL) cells, in order to better diagnose and understand PIOL. Methods: We studied ocular specimens from 57 patients with PIOL at the National Eye Institute from 1991 to 2001. Specimens were analyzed for IgH gene rearrangements using microdissection and polymerase chain reaction (PCR). We measured vitreal interleukin (IL)-10 and IL-6 levels by enzyme-linked immunosorbent assay. IL-10 mRNA was studied in PIOL cells using microdissection and reverse transcribed (RT)-PCR. Chemokine and chemokine receptor expression was examined by using immunohistochemistry. Infectious DNA of human herpetic virus-8 ...

Bag Lunch for Lymphoma Campaign Consent to Solicit I, at _ ( Name) ( Company Name) authorize __ to facilitate the Bag Lunch for Lymphoma ( Volunteer Coordinator) Campaign to raise funds for Lymphoma Research Foundation (LRF). The money raised will be used to further our mission to eradicate lymphoma and serve those touched by this disease. LRF is a tax-exempt 501 (c)(3) nonprofit corporation with the Federal Tax ID # 95-4335088. I understand that the Coordinator will be responsible for: • Adhering to workplace solicitation policy • Following instructions and guidelines established by LRF • Publicizing the campaign • Signing up participants • Obtaining necessary company Matching Gift forms • Sending all donations and completed Campaign Wrap-Up forms to LRF • Maintaining/collecting all ...